European full-service contract research organisation (CRO) Pivotal is providing specialised clinical research services for conducting a clinical study in patients suffering from coronavirus.

The clinical trial intends to include up to 300 patients in up to 25 European centres. It has begun with first patients in Madrid.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to Pivotal, the trial will study whether the treatment against the virus with hyperimmune plasma containing antibodies in patients, who have already recovered from the virus, will stand to benefit those patients with Covid-19 acute phase without immunity against SARS-CoV-2.

The trial is designed to be a multicentre, randomised, sequential and adaptive study that will use the plasma extracted from about 200 convalescent Covid-19 patients for the treatment of patients suffering with the acute phase of this disease, compared to standard treatment.

It will be carried out in two phases.

A pilot phase will involve the participation of 100 patients to evaluate the safety of the procedure, as well as obtain more precise parameters on the characteristics of these patients.  Disease´s evolution and clinical results, and also defining the primary objective to be used in the next phase will be carried out in this phase.

The second phase, which is a pivotal phase and involving up to 200 additional patients, will evaluate the safety and efficiency of using plasma from Covid-19 convalescent patients.

Pivotal Data Management and Biostatistics vice-president José Javier García said: “The know-how and excellence in clinical research of the clinical investigators teams, together with Pivotal’s vast experience in research methodology in clinical trials, will allow us to accelerate the research and to test this new treatment regimen in this trial, the potential positive results which could provide a therapeutic tool available to all hospitals, to significantly reduce Covid-19´s mortality.”

Last July, Pivotal announced to support two Phase II clinical trials of a new immunotherapy drug in metastatic melanoma (MM) and non-small cell lung cancer (NSCLC) patients.